Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - glicin; glukoza, brezvodna; glutaminska kislina; histidin; alanin; arginin; asparaginska kislina; fenilalanin; izolevcin; levcin; lizin; metionin; prolin; serin; treonin; triptofan; valin; sojino olje, rafinirano; trigliceridi, srednjeverižni, nasičeni - emulzija za infundiranje - glicin 2,312 g / 1000 ml  glukoza, brezvodna144 g / 1000 ml  glutaminska kislina4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; glukoza, brezvodna 144 g / 1000 ml  glutaminska kislina4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; glutaminska kislina 4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; histidin 1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fe - kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - glicin; glukoza, brezvodna; glutaminska kislina; histidin; alanin; arginin; asparaginska kislina; fenilalanin; izolevcin; levcin; lizin; metionin; prolin; serin; treonin; triptofan; valin; sojino olje, rafinirano; trigliceridi, srednjeverižni, nasičeni - emulzija za infundiranje - glicin 2,312 g / 1000 ml  glukoza, brezvodna144 g / 1000 ml  glutaminska kislina4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; glukoza, brezvodna 144 g / 1000 ml  glutaminska kislina4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; glutaminska kislina 4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; histidin 1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fe - kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - glicin; glukoza, brezvodna; glutaminska kislina; histidin; alanin; arginin; asparaginska kislina; fenilalanin; izolevcin; levcin; lizin; metionin; prolin; serin; treonin; triptofan; valin; sojino olje, rafinirano; trigliceridi, srednjeverižni, nasičeni - emulzija za infundiranje - glicin 2,312 g / 1000 ml  glukoza, brezvodna144 g / 1000 ml  glutaminska kislina4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; glukoza, brezvodna 144 g / 1000 ml  glutaminska kislina4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; glutaminska kislina 4,908 g / 1000 ml  histidin1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fenilalanin4,916 g / 1000 ml  izolevcin3,284 g / 1000 ml  levcin4,384 g / 1000 ml  lizin3,184 g / 1000 ml  metionin2,736 g / 1000 ml  prolin4,76 g / 1000 ml  serin4,2 g / 1000 ml  treonin2,54 g / 1000 ml  triptofan0,8 g / 1000 ml  valin3,604 g / 1000 ml  sojino olje, rafinirano20 g / 1000 ml  trigliceridi, srednjeverižni, nasičeni20 g / 1000 ml; histidin 1,752 g / 1000 ml  alanin6,792 g / 1000 ml  arginin3,78 g / 1000 ml  asparaginska kislina2,1 g / 1000 ml  fe - kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medis, d.o.o. - emulzija za infundiranje - kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun avitum ag - glukoza, brezvodna; kalcijev klorid dihidrat; magnezijev klorid heksahidrat; natrijev hidrogenkarbonat; natrijev klorid - raztopina za hemofiltracijo - glukoza, brezvodna 9 g / 1 ml  kalcijev klorid dihidrat1,98 g / 1 ml  magnezijev klorid heksahidrat0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; kalcijev klorid dihidrat 1,98 g / 1 ml  magnezijev klorid heksahidrat0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; magnezijev klorid heksahidrat 0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; natrijev hidrogenkarbonat 3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; natrijev klorid 10,39 g / 1 ml - zdravila za filtracijo krvi

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunosupresivi - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. , zdravljenje hude, aktivne in postopno revmatoidni artritis pri odraslih, ki še niso bila obdelana z metotreksatom. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita zmanjšuje stopnja napredovanje skupno škodo, merjeno z x-ray in izboljšuje telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno (za učinkovitost v monotherapy glej oddelek 5. adalimumab ni raziskano pri bolnikih, starih manj kot 2 leti. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita zmanjšuje stopnja napredovanje perifernih skupno škodo, merjeno z x-ray pri bolnikih z polyarticular simetrični podtipov bolezni (glej poglavje 5. 1), in izboljša telesno funkcijo. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 in 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; hidradenitis suppurativa; arthritis - imunosupresivi - revmatoidni arthritisimraldi v kombinaciji z metotreksatom, je indicirano za:zdravljenje zmerno do hudo aktivnega revmatoidnega artritisa pri odraslih bolnikih, kadar je odziv na bolezni-spreminjanje anti-revmatičnih drog, vključno z metotreksatom je nezadostna. zdravljenje hude, aktivne in postopno revmatoidni artritis pri odraslih, ki še niso bila obdelana z metotreksatom. imraldi lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno. adalimumab je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisimraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab ni raziskano pri bolnikih, starih manj kot 2 leti. enthesitis-related arthritisimraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asimraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatični arthritisimraldi je primerna za zdravljenje aktivnega in postopno psoriatičnega artritisa pri odraslih, ko je odgovor na prejšnje bolezni spreminjajo anti-revmatičnih zdravljenja z zdravili je bila neustrezna. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5. 1), ter za izboljšanje telesne funkcije. psoriasisimraldi je primerna za zdravljenje zmerno do hudo kronično psoriazo v plakih pri odraslih bolniki, ki so kandidati za sistemsko terapijo. pediatrični plaketo psoriasisimraldi je primerna za zdravljenje hudo kronično psoriazo v plakih pri otrocih in mladostnikih od 4 let, ki so imeli ustreznega odgovora ali so neprimerne kandidate za aktualna terapije in phototherapies. hidradenitis suppurativa (hs)imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 in 5. crohnova diseaseimraldi je indiciran za zdravljenje zmerno do hudo aktivno crohnovo boleznijo, pri odraslih bolnikih, ki še niso odzvali, kljub temu polno in ustrezni tečaj zdravljenja s kortikosteroidi in/ali immunosuppressant; ali, ki ne prenašajo ali imajo medicinske kontraindikacije za takšne terapije. paediatric crohn's diseaseimraldi is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or haveulcerative colitisimraldi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisimraldi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisimraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whomcorticosteroid treatment is inappropriate. paediatric uveitisimraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamid - epilepsija - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - imunosupresivi - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno. adalimumab je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno. adalimumab ni raziskano pri bolnikih, starih manj kot 2 leti. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab je dokazano, da zmanjša stopnjo napredovanja perifernih skupno škodo, merjeno z x-ray pri bolnikih z polyarticular simetrični podtipov bolezni in izboljšanje telesne funkcije. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Evropska unija - slovenščina - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - imunosupresivi - rheumatoid arthritisyuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisyuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab ni raziskano pri bolnikih, starih manj kot 2 leti. enthesitis-related arthritisyuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asyuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatic arthritisyuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab je dokazano, da zmanjša stopnjo napredovanja perifernih skupno škodo, merjeno z x-ray pri bolnikih z polyarticular simetrični podtipov bolezni (glej poglavje 5. 1), ter za izboljšanje telesne funkcije. psoriasisyuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasisyuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 in 5. crohn’s diseaseyuflyma is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaseyuflyma is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitisyuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisyuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisyuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitisyuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.